Sequana Medical NV [SEQUA] vs Fagron NV [FAGR] Detailed Stock Comparison
Sequana Medical NV
Euronext
Loading...
Fagron NV
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sequana Medical NV wins in 7 metrics, Fagron NV wins in 8 metrics, with 0 ties. Fagron NV appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sequana Medical NV | Fagron NV | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 17.65 | N/A |
| Price-to-Book Ratio | N/A | 3.01 | N/A |
| Debt-to-Equity Ratio | -0.90 | 80.02 | Sequana Medical NV |
| PEG Ratio | -1.02 | 15.64 | Sequana Medical NV |
| EV/EBITDA | -5.50 | 11.56 | Sequana Medical NV |
| Profit Margin (TTM) | 74.94% | 9.33% | Sequana Medical NV |
| Operating Margin (TTM) | -17,731.38% | 15.38% | Fagron NV |
| EBITDA Margin (TTM) | N/A | 15.38% | N/A |
| Return on Equity | 100.62% | 17.53% | Sequana Medical NV |
| Return on Assets (TTM) | -116.66% | 8.06% | Fagron NV |
| Free Cash Flow (TTM) | $-20.35M | $69.10M | Fagron NV |
| Dividend Yield | N/A | 1.60% | N/A |
| 1-Year Return | 26.80% | 7.85% | Sequana Medical NV |
| Price-to-Sales Ratio (TTM) | 752.29 | 1.67 | Fagron NV |
| Enterprise Value | $101.22M | $1.83B | Fagron NV |
| EV/Revenue Ratio | 959.48 | 1.99 | Fagron NV |
| Gross Profit Margin (TTM) | 84.98% | N/A | N/A |
| Revenue per Share (TTM) | $0 | $13 | Fagron NV |
| Earnings per Share (Diluted) | $-1.22 | $1.17 | Fagron NV |
| Beta (Stock Volatility) | 0.01 | 0.25 | Sequana Medical NV |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sequana Medical NV vs Fagron NV Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sequana Medical NV | -9.44% | -10.87% | -8.21% | 11.82% | -32.04% | -49.80% |
| Fagron NV | -0.24% | -2.83% | -6.15% | -3.51% | 5.75% | 22.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sequana Medical NV | 26.80% | -79.22% | -79.90% | -81.75% | -81.75% | -81.75% |
| Fagron NV | 7.85% | 48.74% | 8.08% | -12.56% | 61.06% | 61.06% |
Performance & Financial Health Analysis: Sequana Medical NV vs Fagron NV
| Metric | SEQUA | FAGR |
|---|---|---|
| Market Information | ||
| Market Cap | €79.37M | €1.53B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 581,360 | 85,433 |
| 90 Day Avg. Volume | 421,427 | 79,257 |
| Last Close | €1.23 | €20.60 |
| 52 Week Range | €0.47 - €4.39 | €15.14 - €23.50 |
| % from 52W High | -72.03% | -12.34% |
| All-Time High | €12.40 (Jan 04, 2021) | €41.80 (Aug 04, 2014) |
| % from All-Time High | -90.08% | -50.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | 0.11% |
| Quarterly Earnings Growth | N/A | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.75% | 0.09% |
| Operating Margin (TTM) | -177.31% | 0.15% |
| Return on Equity (TTM) | 1.01% | 0.18% |
| Debt to Equity (MRQ) | -0.90 | 80.02 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €-1.00 | €6.86 |
| Cash per Share (MRQ) | €0.07 | €1.22 |
| Operating Cash Flow (TTM) | €-20,258,146 | €120.42M |
| Levered Free Cash Flow (TTM) | €-9,816,691 | €57.07M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.60% |
| Last 12-Month Dividend | N/A | €0.35 |
Valuation & Enterprise Metrics Analysis: Sequana Medical NV vs Fagron NV
| Metric | SEQUA | FAGR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 17.65 |
| Forward P/E | -1.02 | 15.64 |
| PEG Ratio | -1.02 | 15.64 |
| Price to Sales (TTM) | 752.29 | 1.67 |
| Price to Book (MRQ) | N/A | 3.01 |
| Market Capitalization | ||
| Market Capitalization | €79.37M | €1.53B |
| Enterprise Value | €101.22M | €1.83B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 959.48 | 1.99 |
| Enterprise to EBITDA | -5.50 | 11.56 |
| Risk & Other Metrics | ||
| Beta | 0.01 | 0.25 |
| Book Value per Share (MRQ) | €-1.00 | €6.86 |
Financial Statements Comparison: Sequana Medical NV vs Fagron NV
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SEQUA | FAGR |
|---|---|---|
| Revenue/Sales | €342,801 | N/A |
| Cost of Goods Sold | €51,479 | N/A |
| Gross Profit | €291,322 | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | €-5.16M | N/A |
| EBITDA | €-5.07M | N/A |
| Pre-Tax Income | €-5.35M | N/A |
| Income Tax | €-980 | N/A |
| Net Income (Profit) | €-5.35M | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SEQUA | FAGR |
|---|---|---|
| Cash & Equivalents | €3.81M | €115.04M |
| Total Current Assets | €6.42M | €362.56M |
| Total Current Liabilities | €53.21M | €194.71M |
| Long-Term Debt | €357,902 | €376.20M |
| Total Shareholders Equity | €-44.38M | €505.36M |
| Retained Earnings | €-250.68M | €264.87M |
| Property, Plant & Equipment | €1.28M | €193.11M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SEQUA | FAGR |
|---|---|---|
| Operating Cash Flow | €-4.62M | N/A |
| Capital Expenditures | €-35,382 | N/A |
| Free Cash Flow | €-3.23M | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SEQUA | FAGR |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 581,360 | 85,433 |
| Average Daily Volume (90 Day) | 421,427 | 79,257 |
| Shares Outstanding | 52.42M | 72.84M |
| Float Shares | 24.44M | 64.87M |
| % Held by Insiders | 0.22% | 0.05% |
| % Held by Institutions | 0.39% | 0.65% |
Dividend Analysis & Yield Comparison: Sequana Medical NV vs Fagron NV
| Metric | SEQUA | FAGR |
|---|---|---|
| Last 12-Month Dividend | N/A | €0.35 |
| Last 12-Month Dividend Yield | N/A | 1.60% |
| 3-Year Avg Annual Dividend | N/A | €0.30 |
| 3-Year Avg Dividend Yield | N/A | 1.58% |
| 3-Year Total Dividends | N/A | €0.90 |
| Ex-Dividend Date | N/A | May 19, 2025 |